Results 181 to 190 of about 230,793 (312)

Carbon Nanodots Attenuate Lipid Peroxidation in the LDL Receptor Knockout Mouse Brain. [PDF]

Antioxidants (Basel), 2023
Erikson KM, El-Khouri K, Petric R, Tang C, Chen J, Vasquez DEC, Fordahl SC, Jia Z.   +7 more
europepmc   +1 more source

The role of low-density-lipoprotein receptor (LDLR) family members in human coronary artery endothelial cells in response to modified LDL

, 2010
Eva Theres Gensberger
openalex   +1 more source

Protein deglycosylation can drastically affect the cellular uptake [PDF]

, 2019
Ghazaryan, A., Landfester, K., Mailänder, V.   +2 more
core   +2 more sources

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

Identification of Two Residues within the LDL-A Module of Tva That Dictate the Altered Receptor Specificity of Mutant Subgroup A Avian Sarcoma and Leukosis Viruses

, 2005
Tia Rai, Michael Caffrey, Lijun Rong
openalex   +1 more source

Left ventricular diastolic dysfunction worsens prognosis in patients with heart failure due to dilated cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1183-1193, April 2025.
Abstract Aims The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non‐acutely decompensated patients with DCM ...
Mateusz Winiarczyk, Ewa Dziewięcka, Sylwia Wiśniowska‐Śmiałek, Agnieszka Stępień, Katarzyna Graczyk, Agata Leśniak‐Sobelga, Marta Hlawaty, Jakub Woźniak, Maryia Savitskaya, Katarzyna Holcman, Magdalena Kostkiewicz, Piotr Podolec, Paweł Rubiś   +12 more
wiley   +1 more source

The Constituents of <i>Phyllanthus emblica</i> Fruit Ameliorate Hyperlipidemia Through the Modulation of SREBPs, HMG-CoA Reductase, and LDL Receptor Pathway. [PDF]

Scientifica (Cairo)
Kuddus SA, Shohag MH, Yaseen QI, Ahmed L, Kashfia AT, Islam FB, Khan SI, Karim R, Hossain MM, Alam MA, Khan F.   +10 more
europepmc   +1 more source

ANKS1A regulates LDL receptor-related protein 1 (LRP1)-mediated cerebrovascular clearance in brain endothelial cells. [PDF]

Nat Commun, 2023
Lee J, Lee H, Lee H, Shin M, Shin MG, Seo J, Lee EJ, Park SA, Park S.   +8 more
europepmc   +1 more source

Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor [PDF]

, 2017
Sarah Duellman, Thomas Machleidt, James J. Cali, Jolanta Vidugirienė   +3 more
openalex   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

ESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen, Jiahao Shi, Yue Wu, Lizhu Miao, Zilin Wang, Yixuan Wang, Siwei Xu, Yu Lou   +7 more
wiley   +1 more source